Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Register for OCRFA's Ovarian Cancer National Conference
Join us for an informative and transformative weekend of inspiration and hope, July 13-15 in Washington DC. Meet other survivors, patients and caregivers, hear from experts, and make lasting connections with others who have been touched by ovarian cancer.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
Many factors can increase or decrease a woman's risk of developing ovarian cancer.
- Family history of breast, ovarian or colon cancer
- Genetic mutations like BRCA
- Increased age
- Use of oral contraceptives
Know the Symptoms
- Difficulty Eating
- Pelvic / Abdominal Pain
- Urinary Frequency
If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.
Spring Advocacy Day
OCRFA and our amazing advocates brought #TealAction to Capitol Hill on March 6, highlighting the need for increased ovarian cancer research funding and support at the federal level. Together, we are the voice of the ovarian cancer community. Join us for our next Advocacy Day on July 16th!
(July 12, 2018) A study involving 58,472 women between 1994 and 2015 concluded that assisted reproductive treatment, or ART, did not lead to an increased risk of ovarian cancer. Originally it was thought that the hormones used in ART would increase ovarian activity, which would in turn increase one’s risk of ovarian cancer. However, data… More
(July 2, 2018) Last month the American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, IL. Thirty nine thousand people from around the world attend to learn about the latest in cancer research. Ovarian cancer survivor and research advocate Annie Ellis attended the meeting and wrote a report highlighting some of the… More
(June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery. A phase III trial studied 1,873 women who had not had any prior treatments for stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. Once the women had undergone… More
OCRFA’s 2018 Conference will be held July 13-15, in Washington, DC. The conference will be fol...July 13 - July 15
OCRFA’s indoor cycling event comes to Tampa, FL on September 22, 2018. Ride for a cure for ova...September 22 @ 11:30 am - 1:00 pm EDT
Super Saturday is now Super September! OCRFA’s iconic Super Saturday has a new name, a new dat...September 27 - September 28